← boardnext 2026-11-28next 2027-02next 2027-03next 2027-07-30next 2027-09next 2027-09-30next 2029-04-05next 2029-10-18next 2031-01
GMAB
Genmabdistress 1/10 · well-funded / low risk$28.69-1%today-19% from 52w high
Lead: Diffuse Large B-Cell Lymphoma · est. market ~$18B (approx, global)
Revenue
$896M
Liquidity
$1561M
Runway
—
Shares 1y
—
Price & events
-13.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-1.0%
1W
+10.6%
1M
+6.3%
3M
-15.3%
6M
+25.4%
1Y
+2.7%
2Y
-36.0%
5Y
-29.6%
All
Overview
- Volume
- 135.21K
- 52 Week Range
- $21.08 – $35.34
- Float Shares
- 606.43M
- Short %
- 1.37%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 13.58%
- RVOL
- 0.07x
- Beta
- 0.69
Pipeline stages · 9 programs
GEN1042, Pembrolizumab, Cisplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Rina-S, Bevacizumab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Epcoritamab, Prednisone, Rituximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Acasunlimab, Pembrolizumab, Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Epcoritamab (monotherapy), Epcoritamab, Rituximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
rituximab, cyclophosphamide, doxorubicin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GEN1106
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GEN3018
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GEN1079
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 24 trials · 24 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-28 Estimated 50% readout ~2026-12-28 | Phase 1 | GEN1042, Pembrolizumab, Cisplatin | Malignant Solid Tumor | — | active not recruiting |
| 2027-02 Estimated 50% readout ~2027-04-17 | Phase 3 | Rina-S, Paclitaxel, Topotecan | Platinum-resistant Ovarian Cancer | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | Epcoritamab | Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | Epcoritamab, Cyclophosphamide, Rituximab | Diffuse Large B-Cell Lymphoma | — | active not recruiting |
| 2027-07 Estimated 50% readout ~2027-08-15 | Phase 1/2 | Rina-S, Carboplatin, Bevacizumab | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer | — | recruiting |
Show all 24 trials · 19 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-07-30 Estimated 50% readout ~2027-10-13 | Phase 3 | Acasunlimab, Pembrolizumab, Docetaxel | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | — | active not recruiting |
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 3 | Rina-S, Paclitaxel, Topotecan | Platinum-resistant Ovarian Cancer | — | not yet recruiting |
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 1/2 | Epcoritamab (monotherapy), Epcoritamab, Rituximab | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma | — | active not recruiting |
| 2027-09-30 Estimated 50% readout ~2027-11-14 | Phase 1/2 | rituximab, cyclophosphamide, doxorubicin | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | — | active not recruiting |
| 2027-11-22 Estimated 50% readout ~2028-01-06 | Phase 2 | Rina-S | Non-small Cell Lung Cancer (NSCLC) | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | Epcoritamab, rituximab, cyclophosphamide | Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia | — | active not recruiting |
| 2028-03 Estimated 50% readout ~2028-05-15 | Phase 3 | Epcoritamab, Rituximab, Lenalidomide | Diffuse Large B-Cell Lymphoma | — | active not recruiting |
| 2028-09 Estimated 50% readout ~2028-10-16 | Phase 2 | Rina-S | Gastrointestinal Cancers | — | recruiting |
| 2028-10 Estimated 50% readout ~2028-12-15 | Phase 3 | Rina-S, Bevacizumab | Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC | — | recruiting |
| 2028-11 Estimated 50% readout ~2028-12-01 | Phase 1 | Epcoritamab | Non-hodgkin Lymphoma | — | active not recruiting |
| 2029-01 Estimated 50% readout ~2029-02-15 | Phase 1/2 | Epcoritamab | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL) | — | active not recruiting |
| 2029-04-05 Estimated 50% readout ~2029-05-05 | Phase 1 | GEN1106 | Solid Tumors, Urothelial Carcinoma | — | recruiting |
| 2029-08 Estimated 50% readout ~2029-10-15 | Phase 3 | Rina-S, IC | Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | — | recruiting |
| 2029-10-18 Estimated 50% readout ~2029-11-17 | Phase 1 | GEN3018 | R/R AML, R/R HR-MDS, Acute Myeloid Leukemia, Higher-Risk Myelodysplastic Syndrome | — | recruiting |
| 2029-12 Estimated 50% readout ~2030-02-14 | Phase 3 | Rina-S, Bevacizumab, Carboplatin | Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | — | not yet recruiting |
| 2029-12 Estimated 50% readout ~2030-02-14 | Phase 3 | Epcoritamab, Rituximab, Lenalidomide | Follicular Lymphoma (FL) | — | active not recruiting |
| 2031-01 Estimated 50% readout ~2031-01-31 | Phase 1 | GEN1079 | Advanced Solid Tumors | — | recruiting |
| 2032-11 Estimated 50% readout ~2032-12-16 | Phase 2 | Epcoritamab, Lenalidomide, Ibrutinib | Non-Hodgkin Lymphoma | — | recruiting |
| 2037-11 Estimated 50% readout ~2038-01-15 | Phase 3 | Epcoritamab, Prednisone, Rituximab | Follicular Lymphoma (FL) | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $37 (+29% upside) · 11 analysts
- 2026-07-02HC Wainwright & Co.Buy
- 2026-06-23HC Wainwright & Co.Buy
- 2026-04-30HC Wainwright & Co.Buy
- 2026-03-27Wolfe ResearchOutperform
- 2026-03-02Wells FargoOverweight
- 2026-02-23GuggenheimBuy
Competitors — Diffuse Large B-Cell Lymphoma
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- INCYINCYTE CORP$23.1B · D0
- HCMHUTCHMED (China) Ltd$9.7B · D1
- ARVNARVINAS, INC.$525M · D1
- KPTIKaryopharm Therapeutics Inc.$157M · D7
- ADCTADC Therapeutics SA$155M · D3
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23Genmab stock trades steady as recent earnings and pipeline progress frame valuation - Ad-hoc-news.de
- 2026-07-22Genmab: Multiple Late-Stage Readouts Ahead (NASDAQ:GMAB) - Seeking Alpha
- 2026-07-22TD Cowen upgrades Genmab stock rating on drug pipeline confidence - Investing.com
- 2026-07-22TD Cowen upgrades Genmab to buy (hold) - BN - marketscreener.com
- 2026-07-21Novartis' sales of the Genmab drug are better than expected - medwatch.com
- 2026-07-21Goldman Sachs raises Genmab price target to 2,350 Danish kroner (2,300), reiterates buy - BN - marketscreener.com
- 2026-07-20Genmab A/S (GMAB) Stock Analysis: Investor Optimism With A 28.55% Potential Upside - DirectorsTalk Interviews
- 2026-07-20ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.